This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ziopharm's Sarcoma Study and the Feuerstein-Ratain Rule

NEW YORK ( TheStreet) -- Ziopharm (ZIOP - Get Report) is the next challenger to the Feuerstein-Ratain Rule.

Results from the palifosfamide phase III study in sarcoma are expected at the end of the current quarter. This is a make-or-break clinical catalyst for Ziopharm, so let's take a look at what the Feuerstein-Ratain Rule says about predicting the study outcome.

(I know you're impatient so I'll say Ziopharm's chances are somewhat better than Celsion (CLSN - Get Report) but bear with me and read on.)

First, a reminder about the Feuerstein-Ratain (F-R) Rule: University of Chicago oncologist and professor Dr. Mark Ratain and I examined 59 phase III clinical trials of cancer drugs going back 10 years. We found companies with micro-cap market valuations (i.e. market caps less than $300 million) had no chance -- 0% -- of producing positive phase III results.

By contrast, almost 80% of companies with market values greater than $1 billion conducted positive phase III studies. For companies with market values between $300 million and $1 billion, the success rate was 17%.

Importantly, Ratain and I used market values of cancer drug companies four months prior to the release of phase III results. Our findings were published in the Journal of the National Cancer Institute.

The F-R Rule was constructed retrospectively, meaning we used old data to form our hypothesis. But since last year, two prospective challenges -- the unsuccessful phase III trials of Keryx Pharmaceuticals' (KERX - Get Report) perifosine and Celsion's Thermodox -- confirmed the hypothesis behind the F-R Rule.

Which brings us to Ziopharm. Last November, Ziopharm announced the expectation of top-line results from the palifosfamide study in sarcoma "at the end of the first quarter 2013."

For purposes of this analysis, I'm going to assume palifosfamide results could come at any time during March, the last month of the first quarter. Per the F-R Rule, we need to examine Ziopharm's market value in November 2012 -- four months prior to the expected palifosfamide results.

Ziopharm's average share price during November 2012 was $4.45. An outstanding share count of 78.7 million (taken from the company's Sept. 30 10-Q) yields a market value of $350 million.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PCYC $0.00 0.00%
CLSN $1.45 -4.00%
KERX $5.44 3.30%
ZIOP $7.91 -0.88%
AAPL $93.28 -1.60%


Chart of I:DJI
DOW 17,711.19 -119.57 -0.67%
S&P 500 2,055.29 -20.52 -0.99%
NASDAQ 4,754.2870 -51.0040 -1.06%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs